Tagged with association

UK Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional cash to R&D, and incentivise manufacturing through a new GBP 520 million Life Sciences Innovative Manufacturing Fund (LSIMF).   Addressing…

Switzerland Adrian Hunn of Swiss Medtech, shares insights into his role and the future of Switzerland’s medtech sector. He discusses the association’s focus on fostering innovation, navigating regulatory challenges, and promoting international collaboration to position Switzerland as a global leader. Hunn highlights key initiatives, such as supporting digital healthcare, sustainability efforts,…

Switzerland Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to bridge corporate and governmental interests. He explains his current focus on maintaining the strength of the US-Swiss business relationship, especially…

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…

Switzerland Dr Stephan Mumenthaler, director of scienceindustries, highlights Switzerland’s strong position in the healthcare, life sciences, and pharmaceutical sectors and explores the nation’s commitment to innovation, sustainability, and maintaining global competitiveness.   Switzerland remains a premier destination for the healthcare, life sciences, and pharmaceutical industries, consistently ranking among the top countries…

Switzerland Martine Ruggli discusses the evolving role of pharmacists in Switzerland’s healthcare system, addressing challenges and opportunities in digitalization, drug shortages, and regulatory reforms, as well as the need to leverage pharmacists’ expertise more broadly.   Investing in and empowering pharmacists is essential for improving the quality, accessibility, and efficiency of…

Mexico Pedro Casas Alatriste of AmCham Mexico delves into the chamber’s efforts to enhance U.S.-Mexico trade relations, support key industries, and promote sustainable growth amid Mexico’s political transition.   We are entering North America 2.0, poised for renewed growth and collaboration What are the key issues the American Chamber of Commerce…

China Olivier Dessajan, CEO of Colisée China and Co-President of the French Healthcare Alliance, discusses Colisée’s long-term investment strategies in China, the challenges of navigating the local regulatory environment, and the importance of French-Chinese healthcare collaborations.   French companies are committed to the Chinese market, offering superior products and solutions to…

Switzerland Lucas Schalch of Intergenerika examines the challenges confronting Switzerland’s generic and biosimilar sectors, such as high production costs and changing regulations. Schalch underscores the importance of maintaining a favourable economic environment for these industries.   We must work together to sustain a healthy and competitive market, ensuring that the generic…

Mexico Johannes Hauser, managing director of the German-Mexican Chamber of Commerce and Industry (AHK Mexico, or CAMEXA locally), shares the chamber’s functions, which include representing the German private sector in Mexico, with a predominance in the pharmaceutical and medical device industries. In addition, he weighs in on the evolution of German…

Mexico Dr Jesus Navarro explains how his personal experience with his daughter’s rare disease led him to form the Mexican Organization for Rare Diseases (OMER) to support others facing similar challenges. Dr Navarro highlights the lack of a comprehensive registry for rare diseases in Mexico and the need for specific legislation…